Literature DB >> 32348532

Use of OCTA Capillary Perfusion Density Measurements to Detect and Grade Macular Ischemia.

Amy S Babiuch, Atsuro Uchida, Ming Hu, Mehnaz Khan, Sunil K Srivastava, Rishi P Singh, Peter K Kaiser, Aleksandra Rachtiskaya, Jamie L Reese, Justis P Ehlers.   

Abstract

BACKGROUND AND
OBJECTIVE: To compare optical coherence tomography angiography (OCTA) capillary perfusion density (CPD) measurements of normal eyes and eyes with macular ischemia (MI). PATIENTS AND METHODS: AVATAR is an institutional review board-approved, prospective, observational imaging study using the Avanti RTVue XR HD. OCTA reports were reviewed for the presence of MI. Qualitative MI grading was performed, and CPD metrics in the superficial and deep fovea and parafovea were analyzed. A normal eye cohort was identified for comparative assessment.
RESULTS: The MI and normal cohorts included 55 and 58 eyes, respectively. Compared to normal eyes, eyes with MI had significantly lower CPD values in all regions. There was a statistically significant correlation between qualitative MI grade and VA in the superficial (P = .003) and deep plexuses (P = .029). Only deep parafoveal CPD values demonstrated correlation with VA (P = .043).
CONCLUSIONS: Eyes with MI determined by masked qualitative OCTA grading demonstrated significantly reduced CPD values compared to normal eyes. Categorical assessment of MI severity correlated with VA. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:S30-S36.]. Copyright 2020, SLACK Incorporated.

Entities:  

Mesh:

Year:  2020        PMID: 32348532     DOI: 10.3928/23258160-20200401-04

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  1 in total

1.  Deep learning for quality assessment of optical coherence tomography angiography images.

Authors:  Rahul M Dhodapkar; Emily Li; Kristen Nwanyanwu; Ron Adelman; Smita Krishnaswamy; Jay C Wang
Journal:  Sci Rep       Date:  2022-08-12       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.